Respiratory syncytial virus (RSV): Drastic decline in hospitalizations thanks to vaccines and monoclonal antibodies

Respiratory syncytial virus (RSV): Drastic decline in hospitalizations thanks to vaccines and monoclonal antibodies

By Dr. Kyle Muller

We are winning the battle against the RSV virus: the diffusion of vaccines for pregnant women and the elderly reduces cases in the most vulnerable.

Listen to the audio summary of the article

Listen on Spreaker.

Vaccines and monoclonal antibodies, the weapons that we have deployed in recent years against the respiratory syncytial virus (RSV is the most commonly used acronym, from the English Respiratory syncytial virus) are causing a steep decline in patients needing hospitalization due to the pathogen.

The data arriving from Denmark, Scotland, Argentina and Chile, summarized in an article on Naturegive hope that the fight against RSV may reach a turning point, a new season in which serious cases can be avoided.

RSV: what it is and what the symptoms are

RSV is a highly contagious and very common virus that affects the respiratory tract and whose circulation in our country usually reaches its peak between January and February. It most frequently affects children in the first years of life, but can infect patients of any age. It typically causes symptoms of a severe cold, but in some cases it can reach the lower airways and lungs, causing acute bronchiolitis (that is, an infection of the small airways or bronchioles) or pneumonia.

Based on research published in 2025 on The Lancet Respiratory Medicine and which affected families and health services in Italy, Belgium, the Netherlands, Spain and the United Kingdom, RSV is responsible for almost a third of acute respiratory infections in children.

The WHO estimates that every year there are 3.6 million hospitalizations for RSV worldwide and that the virus causes the death of approximately 100,000 children under the age of 5, 97% in low-income countries. But the virus is also particularly dangerous for the elderly and people already suffering from chronic diseases.

Many options to protect ourselves

Today, to prevent RSV infection, vaccines are administered to adults at risk and pregnant women, and monoclonal antibodies are used for newborns.

In Italy, three vaccines against RSV are available: adjuvanted recombinant vaccine, bivalent recombinant vaccine and mRNA vaccine. The first is indicated for adults aged 60 years and older or for those in their 50s who are particularly at risk of RSV disease. The second is suitable for all over 18s and in particular for pregnant women, between the 24th and 36th week: the mother’s antibodies cross the placenta and protect the newborn in the first six months of life, when it is most vulnerable to infection. The third vaccine is indicated for adults over 18 years of age.

For newborns and infants not protected through the mother, monoclonal antibodies are available administered through a single injection, which offer what experts define as immediate passive immunization: rather than actively stimulating the immune system, they bind to the virus and prevent it from attacking cells, offering protection for the entire epidemic season.

What the data say about RSV vaccines and antibodies

In Denmark, where the RSV vaccine has been offered to pregnant women since autumn 2025, in the epidemic season between 2025 and 2026 the number of RSV hospital admissions of children aged 0 to 5 years fell by 75% compared to the average of the previous three seasons.

In Scotland, where the RSV vaccine was initially administered only to the 75-79 age group eligible for vaccination between 2024 and 2025, the vaccine led to a 62% reduction in hospital admissions due to the virus.

In Argentina, vaccination of pregnant women led to a 34% drop in childhood hospitalizations in the Buenos Aires area. In Chile, giving newborns monoclonal antibodies against RSV led to a 77% drop in infant hospitalizations.

According to experts, time and new data will establish which strategies are most advisable for the protection of newborns. Vaccinating mothers is cheaper, and monoclonal antibodies are now used for premature infants or babies born to vaccine-hesitant mothers. Meanwhile, organizations like GAVI, the Vaccine Alliance, are working to introduce RSV vaccines to low- and middle-income countries.

Kyle Muller
About the author
Dr. Kyle Muller
Dr. Kyle Mueller is a Research Analyst at the Harris County Juvenile Probation Department in Houston, Texas. He earned his Ph.D. in Criminal Justice from Texas State University in 2019, where his dissertation was supervised by Dr. Scott Bowman. Dr. Mueller's research focuses on juvenile justice policies and evidence-based interventions aimed at reducing recidivism among youth offenders. His work has been instrumental in shaping data-driven strategies within the juvenile justice system, emphasizing rehabilitation and community engagement.
Published in

Leave a comment